Checkpoint inhibitors, alone, are effective in 25% of patients when administered as a single agent. The goal of the collaboration between Celgene and Jounce is to address the other 75% of patients. The lead program is focused on ICOS, the Inducible T cell CO-Stimulator, a protein on the surface of T cells that can spur an immune response against a patient’s cancer. Continue reading
Tag Archives: immuno-oncology

Mystery of Myeloid-Derived Suppressor Cells in Cancer SOLVED
Researchers at St. Jude Children’s hospital have identified the population of white blood cells that tumors use to propagate their growth AND to suppress the immune system. Continue reading